<p>住友信託控股根據最新提交給證券交易委員會的第 13F 表格，在第二季度減持了百時美施貴寶（NYSE:BMY - Free Report）的持股比例 10.1%。該公司在該時期賣出了 511,497 股，持有該生物製藥公司股票的股份為 4,562,969 股。在最近一個季度結束時，住友信託控股持有的百時美施貴寶股份價值 1.895 億美元。</p>
<p>獲取 <strong>百時美施貴寶</strong> 警報：</p>
<ul>
<li>MarketBeat 周評 - 7/29 - 8/2</li>
</ul>
<p>其他大型投資者最近也買入和賣出了該公司的股票。麥肯錫金融公司在第四季度增持了百時美施貴寶的股份 37.9%。麥肯錫金融公司現在擁有 611,714 股該生物製藥公司的股票，價值 3138.7 萬美元，比上一時期增持了 168,135 股。泰奇財富合作伙伴有限責任公司在第四季度以約 349,000 美元的價格購入了百時美施貴寶的新股份。楽天証券株式會社在第四季度以 44,000 美元的價格購入了百時美施貴寶的新股份。大和證券集團在第四季度增加了對百時美施貴寶的持倉 6.8%。大和證券集團現在擁有 190,525 股該生物製藥公司的股票，價值 977.6 萬美元，比上一時期增持了 12,160 股。最後，Twin Capital Management Inc.在第四季度增持了百時美施貴寶的股份 13.4%。Twin Capital Management Inc.現在擁有 83,162 股該生物製藥公司的股票，價值 426.7 萬美元，比上一時期增持了 9,831 股。目前有 76.41% 的股份由機構投資者和對沖基金持有。</p>
<h2>百時美施貴寶股票表現</h2>
<p>週五午盤交易時，NYSE:BMY 的股價上漲 0.25 美元，達到 49.36 美元。公司股票交易量為 14,161,770 股，相比其平均交易量 15,904,074 股有所下降。百時美施貴寶的一年最低價為 39.35 美元，最高價為 63.41 美元。該股的 50 日移動平均價為 43.74 美元，200 日移動平均價為 46.58 美元。公司的資產負債比為 2.86，速動比率為 0.99，流動比率為 1.16。公司市值為 1,000.6 億美元，市盈率為-15.92，市盈增長比率為 12.51，貝塔係數為 0.44。</p>
<ul>
<li>令人印象深刻的 Q2 業績發佈後，製藥巨頭股價上漲</li>
</ul>
<p>百時美施貴寶（NYSE:BMY - Get Free Report）於 7 月 26 日星期五發布了季度業績報告。該生物製藥公司報告的季度每股收益為 2.07 美元，超過了 1.64 美元的共識預期 0.43 美元。百時美施貴寶的淨利潤率為-14.06%，股東權益回報率為 12.51%。該公司在該季度實現了 122 億美元的收入，超過了 115.4 億美元的分析師預期。與去年同期相比，該公司的季度收入增長了 8.7%。作為一組，股票研究分析師預計，百時美施貴寶今年財年的每股收益為 0.77 美元。</p>
<h2>百時美施貴寶股息公告</h2>
<p>該公司最近還宣佈了季度股息，於 8 月 1 日星期四支付。截至 7 月 5 日星期五持股的股東將獲得 0.60 美元的股息。除息日為 7 月 5 日星期五。這代表年度股息為 2.40 美元，股息率為 4.86%。百時美施貴寶的股息支付比率為-77.42%。</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>3 只高股息股票，現在獲得收入，未來獲得增長</li>
</ul>
<p>BMY 近期成為多份研究報告的主題。BMO 資本市場將百時美施貴寶的目標股價從 55.00 美元下調至 48.00 美元，並在 4 月 26 日的研究報告中將其股票評級設定為&#34;市場表現&#34;。StockNews.com 在 7 月 29 日星期一的研究報告中，將百時美施貴寶的評級從&#34;買入&#34;提升為&#34;強烈買入&#34;。德意志銀行股份公司將百時美施貴寶的目標股價從 53.00 美元下調至 45.00 美元，並在 7 月 23 日的報告中為該公司設定了&#34;持有&#34;評級。TD Cowen 將百時美施貴寶的目標股價從 45.00 美元上調至 53.00 美元，並在 8 月 12 日的研究報告中為該公司設定了&#34;持有&#34;評級。最後，康泰菲茨傑拉德重申了對百時美施貴寶的&#34;中性&#34;評級，並在 7 月 22 日的報告中將該股票的目標股價設定為 45.00 美元。一位股票研究分析師給予該股票賣出評級，十三位給予持有評級，兩位給予買入評級，一位給予強烈買入評級。根據 MarketBeat.com 的數據，百時美施貴寶目前的共識評級為&#34;持有&#34;，平均目標股價為 54.86 美元。</p>
<p><strong>獲取我們關於 BMY 的最新研究報告</strong></p>
<h2>百時美施貴寶簡介（免費報告）</h2>
<p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、市場、分銷和銷售生物製藥產品。其產品涵蓋血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病。該公司的產品包括 Eliquis，用於降低非瓣膜性心房顫動患者中卒中/全身栓塞風險，並用於 DVT/PE 的治療；Opdivo，用於多種抗癌適應症，包括膀胱、血液、CRC、頭頸、RCC、HCC、肺部、黑色素瘤、MPM、胃和食道癌；Pomalyst/Imnovid，用於多發性骨髓瘤；Orencia，用於活動性類風濕關節炎和銀屑病性關節炎；以及 Sprycel，用於費城染色體陽性慢性髓細胞白血病的治療。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們比百時美施貴寶更喜歡的股票</li>
<li>在 52 周高點盈利交易股票</li>
<li>這家小市值財富管理股票可能帶來巨大回報</li>
<li>如何抓住股息增長的好處</li>
<li>Bumble 的估值創歷史新低，它的命運能否改變？</li>
<li>5 個折扣機會供股息增長投資者選擇</li>
<li>MarketBeat 周評 - 8/12 - 8/16</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ Elon 將改變美國經濟？（來自 Porter &amp; Company）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY3"/></p>
<h2>現在是否值得投資$1,000 美元購買百時美施貴寶？</h2>
<p>在考慮購買百時美施貴寶之前，您需要聽到這個消息。</p>
<p>MarketBeat 跟蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買的股票，而百時美施貴寶不在名單上。</p>
<p>雖然百時美施貴寶目前在分析師中有一個 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

百時美施貴寶

<p>三井住友信託控股有限公司（Sumitomo Mitsui Trust Holdings Inc.）減持百時美施貴寶（Bristol-Myers Squibb，NYSE:BMY）的股份 10.1%，持有約 456 萬股，價值 5 億美元，出售了 511,497 股。百時美施貴寶的股價表現波動，分析師對其給出不同評級和價格目標。該公司第二季度每股收益為 1.07 美元，超出預期，並宣佈每股 0.60 美元的季度股息，收益率為 4.86%。機構投資者持有該股的 76.41%，反映出對這家生物製藥公司的重大興趣</p>

<p>Sumitomo Mitsui Trust Holdings Inc. decreased its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 10.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 4,562,969 shares of the biopharmaceutical company's stock after selling 511,497 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned approximately 0.23% of Bristol-Myers Squibb worth $189,500,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>住友信託控股根據最新提交給證券交易委員會的第 13F 表格，在第二季度減持了百時美施貴寶（NYSE:BMY - Free Report）的持股比例 10.1%。該公司在該時期賣出了 511,497 股，持有該生物製藥公司股票的股份為 4,562,969 股。在最近一個季度結束時，住友信託控股持有的百時美施貴寶股份價值 1.895 億美元。</p>
</div><p>Get <strong>Bristol-Myers Squibb</strong> alerts:</p>
<ul>
<li>MarketBeat Week in Review – 7/29 - 8/2</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>百時美施貴寶</strong> 警報：</p>
<ul>
<li>MarketBeat 周評 - 7/29 - 8/2</li>
</ul>
</div><p>Other large investors have also recently bought and sold shares of the company. Mackenzie Financial Corp raised its holdings in shares of Bristol-Myers Squibb by 37.9% during the fourth quarter. Mackenzie Financial Corp now owns 611,714 shares of the biopharmaceutical company's stock valued at $31,387,000 after purchasing an additional 168,135 shares during the period. Tyche Wealth Partners LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter worth about $349,000. Rakuten Securities Inc. bought a new stake in Bristol-Myers Squibb during the fourth quarter worth $44,000. Daiwa Securities Group Inc. grew its position in Bristol-Myers Squibb by 6.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 190,525 shares of the biopharmaceutical company's stock valued at $9,776,000 after buying an additional 12,160 shares during the period. Finally, Twin Capital Management Inc. raised its holdings in shares of Bristol-Myers Squibb by 13.4% in the 4th quarter. Twin Capital Management Inc. now owns 83,162 shares of the biopharmaceutical company's stock worth $4,267,000 after purchasing an additional 9,831 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投資者最近也買入和賣出了該公司的股票。麥肯錫金融公司在第四季度增持了百時美施貴寶的股份 37.9%。麥肯錫金融公司現在擁有 611,714 股該生物製藥公司的股票，價值 3138.7 萬美元，比上一時期增持了 168,135 股。泰奇財富合作伙伴有限責任公司在第四季度以約 349,000 美元的價格購入了百時美施貴寶的新股份。楽天証券株式會社在第四季度以 44,000 美元的價格購入了百時美施貴寶的新股份。大和證券集團在第四季度增加了對百時美施貴寶的持倉 6.8%。大和證券集團現在擁有 190,525 股該生物製藥公司的股票，價值 977.6 萬美元，比上一時期增持了 12,160 股。最後，Twin Capital Management Inc.在第四季度增持了百時美施貴寶的股份 13.4%。Twin Capital Management Inc.現在擁有 83,162 股該生物製藥公司的股票，價值 426.7 萬美元，比上一時期增持了 9,831 股。目前有 76.41% 的股份由機構投資者和對沖基金持有。</p>
</div><h2>Bristol-Myers Squibb Stock Performance</h2>
<div class="lb-trans"><h2>百時美施貴寶股票表現</h2>
</div><p>Shares of NYSE:BMY traded up $0.25 during midday trading on Friday, reaching $49.36. 14,161,770 shares of the company's stock traded hands, compared to its average volume of 15,904,074. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.41. The stock has a 50 day moving average of $43.74 and a 200 day moving average of $46.58. The company has a debt-to-equity ratio of 2.86, a quick ratio of 0.99 and a current ratio of 1.16. The company has a market cap of $100.06 billion, a price-to-earnings ratio of -15.92, a P/E/G ratio of 12.51 and a beta of 0.44.</p>
<ul>
<li>Pharma Giant's Shares Up After Impressive Q2 Earnings Release</li>
</ul>
<div class="lb-trans"><p>週五午盤交易時，NYSE:BMY 的股價上漲 0.25 美元，達到 49.36 美元。公司股票交易量為 14,161,770 股，相比其平均交易量 15,904,074 股有所下降。百時美施貴寶的一年最低價為 39.35 美元，最高價為 63.41 美元。該股的 50 日移動平均價為 43.74 美元，200 日移動平均價為 46.58 美元。公司的資產負債比為 2.86，速動比率為 0.99，流動比率為 1.16。公司市值為 1,000.6 億美元，市盈率為-15.92，市盈增長比率為 12.51，貝塔係數為 0.44。</p>
<ul>
<li>令人印象深刻的 Q2 業績發佈後，製藥巨頭股價上漲</li>
</ul>
</div><p>Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The firm had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same quarter in the prior year, the firm earned $1.75 EPS. The business's revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - Get Free Report）於 7 月 26 日星期五發布了季度業績報告。該生物製藥公司報告的季度每股收益為 2.07 美元，超過了 1.64 美元的共識預期 0.43 美元。百時美施貴寶的淨利潤率為-14.06%，股東權益回報率為 12.51%。該公司在該季度實現了 122 億美元的收入，超過了 115.4 億美元的分析師預期。與去年同期相比，該公司的季度收入增長了 8.7%。作為一組，股票研究分析師預計，百時美施貴寶今年財年的每股收益為 0.77 美元。</p>
</div><h2>Bristol-Myers Squibb Dividend Announcement</h2>
<div class="lb-trans"><h2>百時美施貴寶股息公告</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were given a $0.60 dividend. The ex-dividend date was Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 4.86%. Bristol-Myers Squibb's payout ratio is -77.42%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度股息，於 8 月 1 日星期四支付。截至 7 月 5 日星期五持股的股東將獲得 0.60 美元的股息。除息日為 7 月 5 日星期五。這代表年度股息為 2.40 美元，股息率為 4.86%。百時美施貴寶的股息支付比率為-77.42%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<ul>
<li>3 High-Yield Dividend Stocks for Income Now and Growth Later</li>
</ul>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
<ul>
<li>3 只高股息股票，現在獲得收入，未來獲得增長</li>
</ul>
</div><p>BMY has been the topic of a number of recent research reports. BMO Capital Markets dropped their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a &#34;market perform&#34; rating on the stock in a research note on Friday, April 26th. StockNews.com upgraded Bristol-Myers Squibb from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Monday, July 29th. Deutsche Bank Aktiengesellschaft cut their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a &#34;hold&#34; rating for the company in a report on Tuesday, July 23rd. TD Cowen lifted their price objective on Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a &#34;hold&#34; rating in a research report on Monday, August 12th. Finally, Cantor Fitzgerald restated a &#34;neutral&#34; rating and set a $45.00 target price on shares of Bristol-Myers Squibb in a report on Monday, July 22nd. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of &#34;Hold&#34; and an average target price of $54.86.</p>
<div class="lb-trans"><p>BMY 近期成為多份研究報告的主題。BMO 資本市場將百時美施貴寶的目標股價從 55.00 美元下調至 48.00 美元，並在 4 月 26 日的研究報告中將其股票評級設定為&#34;市場表現&#34;。StockNews.com 在 7 月 29 日星期一的研究報告中，將百時美施貴寶的評級從&#34;買入&#34;提升為&#34;強烈買入&#34;。德意志銀行股份公司將百時美施貴寶的目標股價從 53.00 美元下調至 45.00 美元，並在 7 月 23 日的報告中為該公司設定了&#34;持有&#34;評級。TD Cowen 將百時美施貴寶的目標股價從 45.00 美元上調至 53.00 美元，並在 8 月 12 日的研究報告中為該公司設定了&#34;持有&#34;評級。最後，康泰菲茨傑拉德重申了對百時美施貴寶的&#34;中性&#34;評級，並在 7 月 22 日的報告中將該股票的目標股價設定為 45.00 美元。一位股票研究分析師給予該股票賣出評級，十三位給予持有評級，兩位給予買入評級，一位給予強烈買入評級。根據 MarketBeat.com 的數據，百時美施貴寶目前的共識評級為&#34;持有&#34;，平均目標股價為 54.86 美元。</p>
</div><p><strong>Get Our Latest Research Report on BMY</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 BMY 的最新研究報告</strong></p>
</div><h2>Bristol-Myers Squibb Profile (Free Report)</h2>
<div class="lb-trans"><h2>百時美施貴寶簡介（免費報告）</h2>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、市場、分銷和銷售生物製藥產品。其產品涵蓋血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病。該公司的產品包括 Eliquis，用於降低非瓣膜性心房顫動患者中卒中/全身栓塞風險，並用於 DVT/PE 的治療；Opdivo，用於多種抗癌適應症，包括膀胱、血液、CRC、頭頸、RCC、HCC、肺部、黑色素瘤、MPM、胃和食道癌；Pomalyst/Imnovid，用於多發性骨髓瘤；Orencia，用於活動性類風濕關節炎和銀屑病性關節炎；以及 Sprycel，用於費城染色體陽性慢性髓細胞白血病的治療。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Bristol-Myers Squibb</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>This Small Cap Wealth Management Stock Could Provide Big Returns</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>Bumble's Valuation Hits an All-Time Low, Can Its Fortunes Change?</li>
<li>5 discounted opportunities for dividend growth investors</li>
<li>MarketBeat Week in Review – 8/12 - 8/16</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>五隻我們比百時美施貴寶更喜歡的股票</li>
<li>在 52 周高點盈利交易股票</li>
<li>這家小市值財富管理股票可能帶來巨大回報</li>
<li>如何抓住股息增長的好處</li>
<li>Bumble 的估值創歷史新低，它的命運能否改變？</li>
<li>5 個折扣機會供股息增長投資者選擇</li>
<li>MarketBeat 周評 - 8/12 - 8/16</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Elon to Transform U.S. Economy? (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ Elon 將改變美國經濟？（來自 Porter &amp; Company）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8867&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Bristol-Myers Squibb right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 美元購買百時美施貴寶？</h2>
</div><p>Before you consider Bristol-Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買百時美施貴寶之前，您需要聽到這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買的股票，而百時美施貴寶不在名單上。</p>
</div><p>While Bristol-Myers Squibb currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然百時美施貴寶目前在分析師中有一個 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

三井住友信託控股公司持有百時美施貴寶（紐約證券交易所代碼：BMY）1.895 億美元的持股